1. Home
  2. PRG vs COLL Comparison

PRG vs COLL Comparison

Compare PRG & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PROG Holdings Inc.

PRG

PROG Holdings Inc.

HOLD

Current Price

$36.26

Market Cap

1.3B

ML Signal

HOLD

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$34.18

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRG
COLL
Founded
2020
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
PRG
COLL
Price
$36.26
$34.18
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
$50.00
$51.40
AVG Volume (30 Days)
387.0K
444.9K
Earning Date
04-29-2026
05-07-2026
Dividend Yield
1.45%
N/A
EPS Growth
N/A
N/A
EPS
0.89
1.73
Revenue
$2,409,223,000.00
$780,567,000.00
Revenue This Year
$23.77
$8.01
Revenue Next Year
$7.91
N/A
P/E Ratio
$39.92
$19.44
Revenue Growth
N/A
23.62
52 Week Low
$25.80
$26.72
52 Week High
$41.14
$50.79

Technical Indicators

Market Signals
Indicator
PRG
COLL
Relative Strength Index (RSI) 67.66 49.11
Support Level $32.07 $31.36
Resistance Level $36.71 $36.22
Average True Range (ATR) 1.49 1.27
MACD 0.62 0.23
Stochastic Oscillator 92.84 51.01

Price Performance

Historical Comparison
PRG
COLL

About PRG PROG Holdings Inc.

PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Share on Social Networks: